pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ozempic · news · pharmadog
← back to Ozempic
News mentioning Ozempic
216
stories
1d
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
biopharma dive
1d
Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck
endpoints
2d
STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
stat
3d
STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
stat
3d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
6d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
7d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
8d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
9d
STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
stat
9d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
10d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
10d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
10d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
10d
#AHA26: Lilly gets another sleep apnea win, this time with obesity pill
endpoints
10d
Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...
raps
13d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
14d
Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitor
fiercebiotech
15d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
15d
STAT+: Ultragenyx cuts staff after another study fails
stat
15d
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
biospace
15d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
15d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
20d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
20d
STAT+: How a simple UTI turns into a $1,756 bill
stat
21d
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides
stat
21d
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
stat
21d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
21d
Opinion: Health care needs buyers willing to say no
stat
← prev
page 1 of 8
next →